Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
If a company builds assets at 27% a year, faster than its revenue growth rate of 11.2% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Chengdu Olymvax Biopharmaceuticals's average Total Assets Growth Rate was 17.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 16.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 27.90% per year.
During the past 13 years, Chengdu Olymvax Biopharmaceuticals's highest 3-Year average Total Assets Growth Rate was 41.80%. The lowest was -1.10%. And the median was 25.55%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Chengdu Olymvax Biopharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Chengdu Olymvax Biopharmaceuticals Total Assets Related Terms
Chengdu Olymvax Biopharmaceuticals Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Olymvax Biopharmaceuticals Total Assets Chart
Chengdu Olymvax Biopharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Total Assets of ¥2,019.9 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors.
Is Chengdu Olymvax Biopharmaceuticals' Total Assets too high?
Chengdu Olymvax Biopharmaceuticals' current Total Assets is ¥2,019.9 Mil. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Total Assets compare to VRTX and REGN?
Chengdu Olymvax Biopharmaceuticals' Total Assets of ¥2,019.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current Total Assets is ¥2,019.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.17, compared to a current price of ¥25.63 — trading 10.6% above its estimated fair value. The current Total Assets is ¥2,019.9 Mil. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Total Assets is ¥2,019.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥25.63 is trading 10.6% above its estimated GF Value™ of ¥23.17.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.
Key valuation signals for SHSE:688319:
Total Assets: ¥2,019.9 Mil
GF Value™: ¥23.17 vs. price of ¥25.63 (10.6% above fair value)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Business Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score
Get the complete analysis for SHSE:688319
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
